Lower Urinary Tract Symptoms and Erectile Dysfunction: Co-Morbidity or Typical "Aging Male" Symptoms? Results of the "Cologne Male Survey"

European Urology

Volumn 44, Issue 5, 2003, Pages 588-594

  Braun, M H ^a   Sommer, F ^a   Haupt, G ^a   Mathers, M J ^b   Reifenrath, B ^a   Engelmann, U H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Urological Ambulatory   (Germany)

Author keywords

Co morbidity; Epidemiology; Erectile dysfunction; LUTS

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; ATTITUDE; COMORBIDITY; ERECTILE DYSFUNCTION; GERMANY; HEALTH SURVEY; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; PATHOPHYSIOLOGY; PENIS ERECTION; PREVALENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUESTIONNAIRE; RISK FACTOR; SYMPTOMATOLOGY;

EID: 0242320983     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00358-0     Document Type: Article

References (45)

1. Bach D, Brühl P. Epidemiologie, Ätiologie, Pathogenese und Symptomatik der benignen Prostatahyperplasie. In: Sökeland J, editor. Benigne Prostata-Hyperplasie. Stuttgart: Georg Thieme Verlag; 1995. p. 2.1-2.9.
2. Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urol 2000;56(Suppl):3-6.
3. Braun M, Klotz T, Klingebiel W, Schwarzer U, Engelmann U. Benigne Prostatahyperplasie und erektile Dysfunktion, wer ist der primär behandelnde Arzt? Urologe B 1999;39:372-5.
4. Burger B, Weidner W, Altwein JE. Prostate and sexuality: an overview. Eur Urol 1999;35:177-84.
5. Namasivayam S, Minhas S, Brooke J, Joyce AD, Prescott S, Eardley I. The evaluation of sexual function in men presenting with symptomatic benign prostatic hyperplasia. Br J Urol 1998;82: 842-6.
6. Braun M, Klotz T, Reifenrath B, Wassmer G, Engelmann U. KEED-erster deutschsprachig validierter Fragebogen zur Erfassung der männlichen sexuellen Funktion. Akt Urol 1998;29:300-5.
7. Carro JC, Raynaud JP, Koch G, Chisholm GD. Di Silverio F, Teillac P, et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomised international study of 1098 patients. Prostate 1996;29:231-40.
8. Traish A, Kim NN, Moreland RB, Goldstein I. Role of alpha adrenergic receptors in erectile function. Int J Impot Res 2000; 12(Suppl 1):S48-63.
9. Lukac B, Léplège A, Thibault P, Jardin A. Prospective study of men with clinical prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 1996;48:731-40.
10. Buzelin JM, Roth S, Gefriaud-Ricouard C, Delauche-Cavallier MC. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. Eur Urol 1997;31:190-8.
11. Debruyne FM, Jardin A, Colloi D, Resel L, Witjes WP, Delauche-Cavallier MC, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998;34:169-75.
12. Schulman CC, Lock TM, Buzelin JM, Boeminghaus F, Stephenson TP, Talja M, European Tamsulosin Study Group. Long-term use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol 2001;166:1358-63.
13. Chapple CR, Wyndaele JJ, Nording J, Boeminghaus F, Ypma AFGVM, Abrams P. Tamsolusin, the first prostate selective α1A-adrenoreceptor antagonist. Eur Urol 1996;29:155-67.
14. Abrams P, Schulman CC, Vaage S, European Tamsolusin Group. Tamsolusin, a selective alpha1c-adrenoreceptor antagonist: a randomised, controlled trail in patients with benign prostatic obstruction (symptomatic BPH). Br J Urol 1995;76:325-36.
15. Lepor H. Phase III multicenter placebo-controlled study of Tamsolusin in benign prostatic hyperplasia. Urology 1998:51: 892-900.
16. Roehrborn CG, Oesterling JE, Auerbach S. Kaplan SA, Llyod LK, Milam DE, et al. The hytrin community assessment trial study (HYCAT): a one year study of Terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996;47:159-68.
17. Puente JG, Swooney M, Cary MM, Roehrborn CG, for the PREDICT investigators. Relationship between age, lower urinary tract symptoms (LUTS) and various domains on erectile dysfunction in 1,098 patients with BPH in the PREDICT study. J Urol 1998;159(Suppl) [Abstract 1272].
18. Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies on Benign Prostatic Hyperplasia Study Group. J Urol 1998;160:1358-67.
19. Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998;51: 677-86.
20. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338:557-63.
21. Bruskewitz RC, Larsen EH, Madsen PO, Dorflinger T. 3-year followup of urinary symptoms after transurethral resection of the prostate. J Urol 1986;136:613-5.
22. Doll HA, Black NA, McPherson K, Flood AB, Williams GB, Smith JC. Mortality, morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy. J Urol 1992;147:1566-73.
23. Libman E, Fichten CS, Creti L, Weinstein N, Amsel R, Brender W. Transurethral prostatectomy: differential effects of age category and presurgery sexual functioning on postprostatectomy sexual adjustment. J Behav Med 1989; 12:469-85.
24. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995;12;332:75-9.
25. Tscholl R, Largo M, Poppinghaus E, Recker E, Subotic B. Incidence of erectile impotence secondary to transurethral resection of benign prostatic hyperplasia, assessed by preoperative and postoperative Snap Gauge tests. J Urol 1995;153:1491-3.
26. Bieri S, Iselin CE, Rohner S. Capsular perforation localization and adenoma size as prognostic indicators of erectile dysfunctional after transurethral prostatectomy. Scand J Urol Nephrol 1997;31:545-8.
27. Padma-Nathan K, Krane RJ. Impotence and prostate surgery. In: Fitzpatrick JM, Krane RJ, editors. The Prostate. London: Churchill Livingstone; 1989. p. 197-205.
28. Hammadeh MY, Madaan S, Singh M, Philp T. Two-year follow-up of a prospective randomised trial of electrovaporization versus resection of prostate. Eur Urol 1998;34:188-92.
29. Arai Y, Okubo K, Okada T, Maekawa S, Aoki Y, Maeda H. Interstitial laser coagulation for management of benign prostatic hyperplasia: a Japanese experience. J Urol 1998;159:1961-5.
30. De la Rosette JJ, Muschter R, Lopez MA, Gillatt D. Interstitial laser coagulation in the treatment of benign prostatic hyperplasia using a diode-laser system with temperature feedback. Br J Urol 1997;80: 433-8.
31. Perlmutter AP, Muschter R. Interstitial laser prostatectomy. Mayo Clin Proc 1998;73:903-7.
32. Francisca EA, d'Ancona FC, Meuleman EJ, Debruyne FM, de la Rosette JJ. Sexual function following high energy microwave thermotherapy: results of a randomized controlled study comparing transurethral microwave thermotherapy to transurethral prostatic resection. J Urol 1999;161:486-90.
33. Roehrbom CG, Issa MM, Bruskewitz RC, Naslund MJ, Oesterling JE, Perez-Marrero R, et al. Transurethral needle ablation for benign prostatic hyperplasia: 12-month results of a prospective, multicenter U.S. study. Urology 1998;51:415-21.
34. Campo B, Bergamaschi F, Corrada P, Ordesi G. Transurethral needle ablation (TUNA) of the prostate: a clinical and urodynamic evaluation. Urology 1997;49:847-50.
35. Schulman CC, Zlotta AR. Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: early clinical experience. Urology 1995;45:28-33.
36. Dixon CM. Transurethral needle ablation for the treatment of benign prostatic hyperplasia. Urol Clin N Am 1995;22:441-4.
37. Steele GS, Sleep DJ. Transurethral needle ablation of the prostate: a urodynamic based study with 2-year followup. J Urol 1997;158: 1834-8.
38. Kaiser FE, Morely JE. Gonadotropins, testosterone and the aging male. Neurobiol Aging 1994;15:559-63.
39. Morely JE, Kaiser FE. Sexual function with advancing age. Med Clin N Am 1989;73:1483-95.
40. Schulman C, Lunenfeld B. The ageing male. World J Urol 2002;20: 4-10.
41. Skakkeback N, Bancroft J, Davidson DW. Adrogen replacement with oral testoserone undecanoate in hypogonadal men: a double-blind controlled study. Clin Endocrinol 1981;14:49-55.
42. Ahn HS, Park CM, Lee SW. The clinical relevance of sex hormone levels and sexual activity in the ageing male. BJU Int 2002;89: 526-30.
43. Derouet H, Lehmann J, Stamm B, et al. Age dependent secretion of LH and ACTH in healthy men and patients with erectile dysfunction. Eur Urol 2002;41:144-53.
44. Wu SF, Sun HZ, Qi XD, Tu ZH. Effect of epristeride on the expression of IGF-1 and TGF-beta receptors inandrogen-induced castrared rat prostate. Exp Bil Med 2001;226:954-60.
45. Dahiya R, Chui R, Perinchery G, Nakajima K, Oh BR, Lue TF. Differential gene expression of growth factors in young and old rat penile tissues is associated with erectile dysfunction. Int J Impot Res 1999;11:201-6.